|
1
|
Li X, Sun T, Li H, Liu J, Huang N, Liu S. The Novel-B-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Esophageal Carcinoma. J Gastrointest Cancer 2024:10.1007/s12029-024-01083-x. [PMID: 38963643 DOI: 10.1007/s12029-024-01083-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/15/2024] [Indexed: 07/05/2024]
Abstract
BACKGROUND The current understanding of the prognostic significance of B cells and their role in the tumor microenvironment (TME) in esophageal carcinoma (ESCA) is limited. METHODS We conducted a screening for B-cell-related genes through the analysis of single-cell transcriptome data. Subsequently, we developed a B-cell-related gene signature (BRGrisk) using LASSO regression analysis. Patients from The Cancer Genome Atlas cohort were divided into a training cohort and a test cohort. Patients were categorized into high- and low-risk groups based on their median BRGrisk scores. The overall survival was assessed using the Kaplan-Meier method, and a nomogram based on BRGrisk was constructed. Immune infiltration profiles between the risk groups were also compared. RESULTS The BRGrisk prognostic model indicated significantly worse outcomes for patients with high BRGrisk scores (p < 0.001). The BRGrisk-based nomogram exhibited good prognostic performance. Analysis of immune infiltration revealed that patients in the high-BRGrisk group had notably higher levels of immune cell infiltration and were more likely to be in an immunoresponsive state. Enrichment analysis showed a strong correlation between the prognostic gene signature and cancer-related pathways. IC50 results indicated that patients in the low-BRGrisk group were more responsive to common drugs compared to those in the high-BRGrisk group. CONCLUSIONS This study presents a novel BRGrisk that can be used to stratify the prognosis of ESCA patients and may offer guidance for personalized treatment strategies aimed at improving prognosis.
Collapse
Affiliation(s)
- Xinhong Li
- Department of Oncohematology, Norinco General Hospital, Xi'an, Shaanxi, 710061, China
| | - Tongyu Sun
- Hepatobiliary and Vascular Surgery, Norinco General Hospital, Xi'an, Shaanxi, 710061, China
| | - Hongyan Li
- Department of Radiology, Norinco General Hospital, Xi'an, Shaanxi, 710061, China
| | - Juan Liu
- Department of Oncohematology, Norinco General Hospital, Xi'an, Shaanxi, 710061, China
| | - Na Huang
- National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China
| | - Surong Liu
- Department of Oncohematology, Norinco General Hospital, Xi'an, Shaanxi, 710061, China.
| |
Collapse
|
|
2
|
Wagner A, Garner-Spitzer E, Auer C, Gattinger P, Zwazl I, Platzer R, Orola-Taus M, Pichler P, Amman F, Bergthaler A, Huppa JB, Stockinger H, Zielinski CC, Valenta R, Kundi M, Wiedermann U. Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants. Vaccines (Basel) 2024; 12:518. [PMID: 38793769 PMCID: PMC11125692 DOI: 10.3390/vaccines12050518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 04/30/2024] [Accepted: 05/03/2024] [Indexed: 05/26/2024] Open
Abstract
Patients with multiple myeloma (MM) are a heterogenous, immunocompromised group with increased risk for COVID-19 morbidity and mortality but impaired responses to primary mRNA SARS-CoV-2 vaccination. The effects of booster vaccinations and breakthrough infections (BTIs) on antibody (Ab) levels and cross-protection to variants of concern (VOCs) are, however, not sufficiently evaluated. Therefore, we analysed humoral and cellular vaccine responses in MM patients stratified according to disease stage/treatment into group (1) monoclonal gammopathy of undetermined significance, (2) after stem cell transplant (SCT) without immunotherapy (IT), (3) after SCT with IT, and (4) progressed MM, and in healthy subjects (prospective cohort study). In contrast to SARS-CoV-2 hu-1-specific Ab levels, Omicron-specific Abs and their cross-neutralisation capacity remained low even after three booster doses in a majority of MM patients. In particular, progressed MM patients receiving anti-CD38 mAb and those after SCT with IT were Ab low responders and showed delayed formation of spike-specific B memory cells. However, MM patients with hybrid immunity (i.e., vaccination and breakthrough infection) had improved cross-neutralisation capacity against VOCs, yet in the absence of severe COVID-19 disease. Our results indicate that MM patients require frequent variant-adapted booster vaccinations and/or changes to other vaccine formulations/platforms, which might have similar immunological effects as BTIs.
Collapse
Affiliation(s)
- Angelika Wagner
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| | - Erika Garner-Spitzer
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| | - Claudia Auer
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| | - Pia Gattinger
- Center for Pathophysiology, Infectiology and Immunology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria; (P.G.); (R.V.)
| | - Ines Zwazl
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| | - René Platzer
- Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University Vienna, 1090 Vienna, Austria; (R.P.); (F.A.); (A.B.); (J.B.H.); (H.S.)
| | - Maria Orola-Taus
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| | - Peter Pichler
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| | - Fabian Amman
- Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University Vienna, 1090 Vienna, Austria; (R.P.); (F.A.); (A.B.); (J.B.H.); (H.S.)
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, CeMM, 1090 Vienna, Austria
| | - Andreas Bergthaler
- Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University Vienna, 1090 Vienna, Austria; (R.P.); (F.A.); (A.B.); (J.B.H.); (H.S.)
- Research Center for Molecular Medicine of the Austrian Academy of Sciences, CeMM, 1090 Vienna, Austria
| | - Johannes B. Huppa
- Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University Vienna, 1090 Vienna, Austria; (R.P.); (F.A.); (A.B.); (J.B.H.); (H.S.)
| | - Hannes Stockinger
- Center of Pathophysiology, Infectiology and Immunology, Institute for Hygiene and Applied Immunology, Medical University Vienna, 1090 Vienna, Austria; (R.P.); (F.A.); (A.B.); (J.B.H.); (H.S.)
| | - Christoph C. Zielinski
- Wiener Privatklinik, and Central European Cooperative Oncology Group (CECOG), Central European Cancer Center, 1090 Vienna, Austria;
| | - Rudolf Valenta
- Center for Pathophysiology, Infectiology and Immunology, Department of Pathophysiology and Allergy Research, Medical University of Vienna, 1090 Vienna, Austria; (P.G.); (R.V.)
- Karl Landsteiner University of Health Sciences, 3500 Krems, Austria
| | - Michael Kundi
- Center for Public Health, Medical University Vienna, 1090 Vienna, Austria;
| | - Ursula Wiedermann
- Institute of Specific Prophylaxis and Tropical Medicine, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, 1090 Vienna, Austria; (A.W.); (E.G.-S.); (C.A.); (I.Z.); (M.O.-T.); (P.P.)
| |
Collapse
|
|
3
|
Sharma P, Julius C, Leal H, Munjal RS, Dhillon G, Verma RK, Grewal H, Buddhavarapu VS, Kashyap R. Proliferative Glomerulonephritis With Monoclonal IgG Deposits: Another Unusual Presentation. Cureus 2024; 16:e56957. [PMID: 38665715 PMCID: PMC11044103 DOI: 10.7759/cureus.56957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2023] [Accepted: 03/25/2024] [Indexed: 04/28/2024] Open
Abstract
Proliferative glomerulonephritis with monoclonal immunoglobulin G (IgG) deposits (PGNMID) is a relatively rare diagnosis with variable presentation. When detectable, the disease is typically indolent rather than malignant and recurs in transplant cases. Here, we report a case of PGNMID, which presented clinically as rapidly progressive glomerulonephritis (RPGN). The patient presented to his primary care physician's office with diarrhea for one day and was admitted for acute kidney injury. Urine sediment was active, and the patient had nephrotic range proteinuria. Serologic workup was negative for any monoclonality: ANA, c-ANCA, and p-ANCA. Kidney biopsy showed diffuse proliferative and crescentic glomerulonephritis with IgG3-kappa restricted deposits, consistent with PGNMID. The patient required dialysis initiation, and corticosteroids were administered. The patient declined further immunomodulatory treatment and remains hemodialysis-dependent. This case highlights the potential for severe renal damage from monoclonal proteins despite an indolent or even undetectable hematologic clone. This entity needs further studies to better understand its immuno-physiological background and develop a standard treatment regimen.
Collapse
Affiliation(s)
- Pranjal Sharma
- Clinical Research, Global Remote Research Program, St. Paul, USA
- Nephrology, Premier Renal Care Associates, Cuyahoga Falls, USA
- Internal Medicine/Nephrology, Northeast Ohio Medical University, Rootstown, USA
| | | | | | | | - Gagandeep Dhillon
- Physician Executive Master of Business Administration, University of Tennessee, Knoxville, USA
- Internal Medicine, University of Maryland Medical Center, Baltimore, USA
| | - Ram K Verma
- Sleep Medicine, Parkview Health System, Fort Wayne, USA
| | - Harpreet Grewal
- Radiology, Florida State University College of Medicine, Pensacola, USA
| | | | - Rahul Kashyap
- Medicine, Drexel University College of Medicine, Philadelphia, USA
- Global Clinical Scholars Research Training, Harvard Medical School, Boston, USA
- Research, Global Remote Research Program, St. Paul, USA
- Critical Care Medicine, Mayo Clinic, Rochester, USA
- Research, WellSpan Health, York, USA
| |
Collapse
|
|
4
|
Chen Y, Tang S. Gut microbiota and immune mediation: a Mendelian randomization study on granulomatosis with polyangiitis. Front Immunol 2023; 14:1296016. [PMID: 38090556 PMCID: PMC10715420 DOI: 10.3389/fimmu.2023.1296016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Accepted: 11/03/2023] [Indexed: 12/18/2023] Open
Abstract
Background The gut microbiota plays a pivotal role in influencing various health outcomes, including immune-mediated conditions. Granulomatosis with Polyangiitis (GPA) is one such condition, and its potential associations with gut microbiota remain underexplored. Method Using a two-sample Mendelian randomization approach, we investigated the causal links between gut microbiota and GPA. We sourced our data from multiple cohorts and consortiums, including the MiBioGen consortium. Our study design incorporated both direct associations and mediation effects of immune traits on the relationship between gut microbiota and GPA. Results Our analysis revealed significant associations between 1 phylum, 1 family 9 genus microbiota taxa and GPA. Furthermore, we identified several immune cell traits that mediated the effects of gut microbiota on GPA. For instance, the family Defluviitaleaceae and genus Defluviitaleaceae UCG011 influenced GPA through CD11c in granulocytes. The mediation effect proportions further elucidated the complex dynamics between gut microbiota exposures, immune markers, and their combined influence on GPA. Conclusion Our findings underscore the intricate relationship between gut microbiota, immune markers, and GPA. The identified associations and mediation effects provide valuable insights into the potential therapeutic avenues targeting gut microbiota to manage GPA.
Collapse
Affiliation(s)
| | - Shilin Tang
- Department of Cardiology, Affliated Haikou Hospital of Xiangya Medical College, Central South University, Haikou, China
| |
Collapse
|